Definition:
- A rare, high-grade soft tissue sarcoma of mesenchymal origin.
- Despite its name, it does not arise from synovium; instead, it originates from primitive mesenchymal cells.
- Characterized by a specific chromosomal translocation:
- t(X;18)(p11;q11) → SS18::SSX fusion gene (diagnostic hallmark).
Epidemiology:
- Accounts for ~5–10% of all soft tissue sarcomas.
- Typically occurs in adolescents and young adults (15–40 years).
- Common sites: extremities near large joints (knee, ankle), but can occur in lung, mediastinum, retroperitoneum.
- Subtypes: biphasic (epithelial + spindle cells), monophasic (spindle only), and poorly differentiated.
- IHC: often positive for EMA, cytokeratin, TLE1.
Clinical course:
- Aggressive behavior, high risk of local recurrence and pulmonary metastases.
- Prognosis influenced by tumor size (>5 cm worse), location, and resection margins.
Treatment:
- Localized disease:
- Surgery with negative margins = cornerstone.
- Radiation therapy often used (neoadjuvant/adjuvant) for local control.
- Role of adjuvant chemotherapy is debated but sometimes used in high-risk cases (usually anthracycline/ifosfamide).
- Metastatic/advanced disease:
- First-line: Doxorubicin ± ifosfamide.
- Other options: high-dose ifosfamide, gemcitabine/docetaxel, trabectedin, pazopanib.
- Ongoing trials with immunotherapy (PD-1 inhibitors, vaccines, TCR therapies).
Pharmacist considerations:
- Chemotherapy backbone: doxorubicin (cardiotoxicity) and ifosfamide (nephro/neurotoxicity, requires mesna).
- Pazopanib: oral TKI option in later lines; monitor for HTN, hepatotoxicity, hand–foot syndrome.
- Myelosuppression is common across regimens → G-CSF may be needed.
- Counsel young patients on fertility preservation.
- Ensure multidisciplinary team approach (surgery, radiation, systemic therapy).
Take-home for BPS/Oncology Pharmacy:
Synovial sarcoma is a rare, translocation-driven soft tissue sarcoma that affects young adults, usually in extremities. Treatment relies on surgery + radiation for localized disease, and anthracycline/ifosfamide-based chemo or targeted agents (pazopanib) for advanced disease. Pharmacists must focus on toxicity prevention, supportive care, and monitoring oral TKI adherence.
Links